Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01 
AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO...
Dosecann Launches Industry-Leading, High-Potency Topical: Dosecann Daily Relief CBD Cream
Dosecann Daily Relief CBD Cream Dosecann Daily Relief CBD Cream TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Today Dosecann, an...
XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has...
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories Upfront and potential milestone...
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
AC – Inflammation was Mild and Decreasing over Time in Cohort 3 AC – Inflammation was Mild and Decreasing over...
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on...
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with...
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting
Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4CAMBRIDGE, Mass., May 01, 2021...
Samsung Bioepis Announces Analytical Similarity Data on SB11 (ranibizumab) at the ARVO Annual Meeting 2021
Analytical assessment demonstrates structural, physicochemical, and biological similarity between SB11 and Lucentis SB11 is under review by the FDA and...
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual...
R1 RCM to Present at Two Upcoming Investor Conferences
CHICAGO, April 30, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform...
Aurora Spine Corporation Announces Fourth Quarter and Fiscal 2020 Financial Results
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 30, 2021 (GLOBE NEWSWIRE)...
Abivax publishes Universal Registration Document 2021 ‘Document d’Enregistrement Universel’
PARIS, FRANCE / ACCESSWIRE / April 30, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing...
Millennium Family Practice: Compassionate, Quality Medical Care
DALLAS, TX / ACCESSWIRE / April 30, 2021 / Millennium Family Practice, in Columbia, Maryland, provides quality medical care for people...
Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference
ImmunopheresisTM is shown to be well-tolerated in treating cancer patients who failed multiple lines of standard therapies SAN DIEGO--(BUSINESS WIRE)--#biotech--Immunicom,...
Cloud DX Announces Retention Of Market Maker
WATERLOO, ON / ACCESSWIRE / April 30, 2021 / Cloud DX (TSXV:CDX) (The Company) a leading Canadian provider of virtual...
Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial Company Q&A Webinar Scheduled for Monday, June 7,...
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022CAMBRIDGE, Mass., April 30,...
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced...
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
A single-day dose of oral ibrexafungerp demonstrates positive clinical outcomes in difficult-to-treat vulvovaginal candidiasis (VVC) patient populations: those with non-albicans...